<DOC>
	<DOCNO>NCT01083641</DOCNO>
	<brief_summary>The purpose study determine effectiveness Estradiol treatment advance breast cancer hormone receptor negative Her2/neu negative . The study also use tumor tissue original diagnosis biopsy may cancer look hormone receptor lab . The tissue leave previous surgery previous biopsy use research test check whether different estrogen receptor ( estrogen receptor beta ) see tumor make estrogen work well .</brief_summary>
	<brief_title>Estrogen Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>histologically cytologically confirm breast cancer metastatic . A formalinfixed paraffin embed tumor block ( prefer ) unstained slide must available either prior biopsy primary tumor metastatic site . . Primary tumor metastatic biopsy lack estrogen progesterone receptor Her2 negative Patients must measurable disease . Eastern Cooperative Oncology Group performance status 01 . Patients bone metastasis baseline must agree treatment intravenous bisphosphonates Subjects may 04 line prior systemic chemotherapy target therapy regimen administer treatment metastatic breast cancer . Age &gt; 18 year Life expectancy great 3 month . Patients must adequate organ marrow function define : systemic chemotherapy , target therapy radiotherapy cancer within 2 week prior enter study Patients receive investigational agent breast cancer treatment . Patients know brain metastasis exclude 3.2.4 History allergic reaction attribute compound similar chemical biologic composition estradiol . Patients condition gastrointestinal tract expect result inability take oral medication Dysfunctional postmenopausal vaginal bleeding . Uncontrolled hypercalcemia/hypocalcemia Prior history active thrombophlebitis , cerebral vascular accident , myocardial infarction , deep venous thrombosis pulmonary embolism . History active hepatic adenoma . Uncontrolled intercurrent illness Pregnant woman exclude study Patients bone metastasis exclude unable receive intravenous bisphosphonate therapy due risk develop hypercalcemia .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>